12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Q-QIV: Phase III data

A double-blind, North American Phase III trial in 1,703 adults showed that Q-QIV met the primary endpoint of non-inferior immunogenicity at day 21 to both control trivalent vaccines containing either a type B strain of Yamagata or Victoria lineage. Non-inferiority was...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >